Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

Add time:08/29/2019    Source:sciencedirect.com

KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.

We also recommend Trading Suppliers and Manufacturers of 2-BROMO-3-METHYL-N-PHENYLBUTANAMIDE (cas 111216-73-0). Pls Click Website Link as below: cas 111216-73-0 suppliers

Prev:A concise total synthesis of (±)-A80915G, a member of the napyradiomycin family of antibiotics
Next:ReviewBiosynthesis and regulation of microbial polyunsaturated fatty acid production)